Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with a first diagnosis of classical Hodgkin lymphoma according to the World Health Organization (WHO) criteria excluding nodular lymphocyte predominant subtype~* Age of 61 years or older~* No previous treatment for Hodgkin lymphoma~* Ann Arbor stages:~  * II with mediastinum/thorax ≥0.33 or extranodal localization and with B symptoms~ * Or III~ * Or IV~* Baseline 18-FluoroDeoxyGlucose (FDG) PET scan (PET0) performed before any treatment with at least one hypermetabolic lesion~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Adequate cardio-pulmonary function with Left Ventricular Ejection Fraction (LVEF) ≥ 50%~* Adequate renal function with creatinine clearance ≥ 40 mL/mn (MDRD formula)~* For patients aged 70 years old and more, a Mini Nutritional Assessment (MNA) ≥ 17~* A minimum life expectancy of 3 months~* Negative Human Immunodeficiency Virus, Hepatitis B (HB) Virus (anti-HB c negativity) and Hepatitis C Virus serologies tests ≤ 30 days before inclusion (except after vaccination)~* Having previously signed a written informed consent~* The patient must be covered by a social security system, if applicable~* Men patient must agree to use an adequate method of contraception during the study treatment and until 6 months after the end of the study treatment.~Exclusion Criteria:~* Any other type of lymphoma including nodular lymphocyte predominant subtype~* Any history of treated Hodgkin lymphoma~* Contra-indication to any drug contained in the chemotherapy regimens~* Any serious active disease (according to the investigator's decision)~* Poor hepatic function (total bilirubin level \> 30 μmol/L or transaminases \> 2.5 maximum normal level) unless these abnormalities are related to the lymphoma~* Poor bone marrow reserve as defined by leukocytes \< 2 G/L or platelets \< 100 G/L, unless related to bone marrow infiltration~* Any history of cancer during the last 3 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. Patients previously diagnosed with prostate cancer are eligible if they fulfil all the followings:~  1. their disease was T1-T2a, N0, M0, with a Gleason score ≤ 7, and a prostate specific antigen (PSA) ≤ 10 ng/mL prior to initial therapy,~ 2. they had definitive curative therapy (i.e. prostatectomy or radiotherapy) ≥ 2 years before Day 1 of Cycle 1,~ 3. at a minimum 2 years following therapy, they had no clinical evidence of prostate cancer and their PSA was undetectable if they underwent prostatectomy or \< 1 ng/mL if they did not undergo prostatectomy~* Severe metabolic disease interfering with normal application of protocol treatment as uncontrolled diabetes mellitus leading to impossibility to perform PET scan~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study~* Adult under tutelage

- Gender: ALL
- Minimum Age: 61 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PVAB regimen (Type: EXPERIMENTAL): Prednisone 40 mg/m2 (PO) Days 1-5 ; Vinblastine 6 mg/m2 (IV) Day 1 ; Doxorubicin 40 mg/m2 (IV) Day 1 ; Bendamustine 120 mg/m2 (IV) Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete